FDA Approves Rasonque for Pancreatic Cancer Treatment

Pancreatic adenocarcinoma accounts for a disproportionately large amount of cancer deaths per year in the U.S.

Aug. 26, 2026

Key Highlights

- Rasonque is a RAS inhibitor approved for metastatic pancreatic adenocarcinoma in adults.
- Taken once daily, it targets tumor growth pathways to improve patient outcomes.
- Clinical trials showed median survival increased to 13.2 months with Rasonque versus 6.7 months with standard therapy.
- The drug is intended for patients who have received prior systemic therapy or are ineligible for multiagent treatments.
- This approval addresses a critical need in pancreatic cancer, which is often diagnosed late and has limited treatment options.

6a8f3c6176f0301981565ecb Pancreatic Cancer

The FDA has approved Rasonque, a RAS inhibitor for pancreatic adenocarcinoma, the most common form of pancreatic cancer.

Rasonque is a tablet taken once daily. It targets multiple forms of a protein called RAS, which is a key driver of tumor growth in most patients with this form of pancreatic cancer.

The approval is specifically for the treatment of adults with metastatic pancreatic adenocarcinoma who have received at least one prior systemic therapy or are not candidates for multiagent systemic therapy.

90-95% of the 67,000 new cases of pancreatic cancer diagnosed annually in the U.S. are pancreatic adenocarcinoma. These cases account for a disproportionately high share of cancer deaths, because it is typically detected late, aggressive, and has limited treatment options.

Rasonque improved median overall survival to 13.2 months compared to 6.7 months for standard chemotherapy in a trial that involved 500 adults.